178 related articles for article (PubMed ID: 38673999)
1. The Catalysis Mechanism of
Valiauga B; Bagdžiūnas G; Sharrock AV; Ackerley DF; Čėnas N
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673999
[No Abstract] [Full Text] [Related]
2. Reduction of quinones and nitroaromatic compounds by Escherichia coli nitroreductase A (NfsA): Characterization of kinetics and substrate specificity.
Valiauga B; Williams EM; Ackerley DF; Čėnas N
Arch Biochem Biophys; 2017 Jan; 614():14-22. PubMed ID: 27986535
[TBL] [Abstract][Full Text] [Related]
3. The structures of E. coli NfsA bound to the antibiotic nitrofurantoin; to 1,4-benzoquinone and to FMN.
Day MA; Jarrom D; Christofferson AJ; Graziano AE; Anderson JLR; Searle PF; Hyde EI; White SA
Biochem J; 2021 Jul; 478(13):2601-2617. PubMed ID: 34142705
[TBL] [Abstract][Full Text] [Related]
4. Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy.
Copp JN; Mowday AM; Williams EM; Guise CP; Ashoorzadeh A; Sharrock AV; Flanagan JU; Smaill JB; Patterson AV; Ackerley DF
Cell Chem Biol; 2017 Mar; 24(3):391-403. PubMed ID: 28262557
[TBL] [Abstract][Full Text] [Related]
5. Oxygen-insensitive nitroreductase E. coli NfsA, but not NfsB, is inhibited by fumarate.
Day MA; Jarrom D; Rajah N; Searle PF; Hyde EI; White SA
Proteins; 2023 May; 91(5):585-592. PubMed ID: 36443029
[TBL] [Abstract][Full Text] [Related]
6. Intracellular complexities of acquiring a new enzymatic function revealed by mass-randomisation of active-site residues.
Hall KR; Robins KJ; Williams EM; Rich MH; Calcott MJ; Copp JN; Little RF; Schwörer R; Evans GB; Patrick WM; Ackerley DF
Elife; 2020 Nov; 9():. PubMed ID: 33185191
[TBL] [Abstract][Full Text] [Related]
7. The 3D-structure, kinetics and dynamics of the E. coli nitroreductase NfsA with NADP
White SA; Christofferson AJ; Grainger AI; Day MA; Jarrom D; Graziano AE; Searle PF; Hyde EI
FEBS Lett; 2022 Sep; 596(18):2425-2440. PubMed ID: 35648111
[TBL] [Abstract][Full Text] [Related]
8. Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.
Johansson E; Parkinson GN; Denny WA; Neidle S
J Med Chem; 2003 Sep; 46(19):4009-20. PubMed ID: 12954054
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of CB1954 reduction by Escherichia coli nitroreductase.
Christofferson A; Wilkie J
Biochem Soc Trans; 2009 Apr; 37(Pt 2):413-8. PubMed ID: 19290872
[TBL] [Abstract][Full Text] [Related]
10. Residue Phe42 is critical for the catalytic activity of Escherichia coli major nitroreductase NfsA.
Yang J; Zhan J; Bai J; Liu P; Xue Y; Yang Q
Biotechnol Lett; 2013 Oct; 35(10):1693-700. PubMed ID: 23801116
[TBL] [Abstract][Full Text] [Related]
11. Oxygen-insensitive nitroreductases NfsA and NfsB of Escherichia coli function under anaerobic conditions as lawsone-dependent Azo reductases.
Rau J; Stolz A
Appl Environ Microbiol; 2003 Jun; 69(6):3448-55. PubMed ID: 12788749
[TBL] [Abstract][Full Text] [Related]
12. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of Two-/Four-Electron Reduction of Nitroaromatics by Oxygen-Insensitive Nitroreductases: The Role of a Non-Enzymatic Reduction Step.
Valiauga B; Misevičienė L; Rich MH; Ackerley DF; Šarlauskas J; Čėnas N
Molecules; 2018 Jul; 23(7):. PubMed ID: 29987261
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of chromate reduction by the Escherichia coli protein, NfsA, and the role of different chromate reductases in minimizing oxidative stress during chromate reduction.
Ackerley DF; Gonzalez CF; Keyhan M; Blake R; Matin A
Environ Microbiol; 2004 Aug; 6(8):851-60. PubMed ID: 15250887
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of major Escherichia coli reductases involved in aerobic nitro and azo reduction.
Mercier C; Chalansonnet V; Orenga S; Gilbert C
J Appl Microbiol; 2013 Oct; 115(4):1012-22. PubMed ID: 23795903
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of NfsA-like nitroreductases from Neisseria meningitidis and Bartonella henselae for enzyme-prodrug therapy, targeted cellular ablation, and dinitrotoluene bioremediation.
Rich MH; Sharrock AV; Hall KR; Ackerley DF; MacKichan JK
Biotechnol Lett; 2018 Feb; 40(2):359-367. PubMed ID: 29147875
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy.
Chan-Hyams JVE; Copp JN; Smaill JB; Patterson AV; Ackerley DF
Biochem Pharmacol; 2018 Dec; 158():192-200. PubMed ID: 30352235
[TBL] [Abstract][Full Text] [Related]
18. E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954.
Vass SO; Jarrom D; Wilson WR; Hyde EI; Searle PF
Br J Cancer; 2009 Jun; 100(12):1903-11. PubMed ID: 19455141
[TBL] [Abstract][Full Text] [Related]
19. Study of the role played by NfsA, NfsB nitroreductase and NemA flavin reductase from Escherichia coli in the conversion of ethyl 2-(2'-nitrophenoxy)acetate to 4-hydroxy-(2H)-1,4-benzoxazin-3(4H)-one (D-DIBOA), a benzohydroxamic acid with interesting biological properties.
Valle A; Le Borgne S; Bolívar J; Cabrera G; Cantero D
Appl Microbiol Biotechnol; 2012 Apr; 94(1):163-71. PubMed ID: 22173483
[TBL] [Abstract][Full Text] [Related]
20. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
Prosser GA; Copp JN; Syddall SP; Williams EM; Smaill JB; Wilson WR; Patterson AV; Ackerley DF
Biochem Pharmacol; 2010 Mar; 79(5):678-87. PubMed ID: 19852945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
